The regulatory landscape for actively personalized cancer immunotherapies

Nature Biotechnology

Volumn 31, Issue 10, 2013, Pages 880-882

  Britten, Cedrik M ^a,b   Singh Jasuja, Harpreet ^c   Flamion, Bruno ^d   Hoos, Axel ^e   Huber, Christoph ^f   Kallen, Karl Josef ^g   Khleif, Samir N ^h   Kreiter, Sebastian ^a   Nielsen, Michaela ⁱ   Rammensee, Hans Georg ^j   Sahin, Ugur ^a,k   Hinz, Thomas ^l   Kalinke, Ulrich ^m  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Ribological GmbH   (Germany)

^c IMMATICS BIOTECHNOLOGIES GMBH   (Germany)

^d University of Namur   (Belgium)

^e GLAXOSMITHKLINE   (United States)

^f Association for Cancer Immunotherapy   (Germany)

^g CureVac GmbH   (Germany)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ Celldex Therapeutics Inc   (United Kingdom)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k BIONTECH AG   (Germany)

^l PAUL EHRLICH INSTITUT   (Germany)

^m INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; SIPULEUCEL T; TUMOR MARKER; VITESPEN;

CANCER IMMUNOTHERAPY; COMPUTER ANALYSIS; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LETTER; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; NEOPLASMS; SOCIAL CONTROL, FORMAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84885659334     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2708     Document Type: Letter

References (15)

1. Sjoblom, T. et al. Science 314, 268-274 (2006).
2. Gerlinger, M. et al. N. Engl. J. Med. 366, 883-892 (2012).
3. Castle, J. C. et al. Cancer Res. 72, 1081-1091 (2012).
4. Matsushita, H. et al. Nature 482, 400-404 (2012).
5. Robbins, P. F. et al. Nat. Med. 19, 747-752 (2013).
6. van Rooij, N. et al. J. Clin. Oncol. doi:10. 1200/ jco. 2012. 47. 7521 (16 September 2013).
7. Vonderheide, R. H. et al. Nat. Med. 19, 1098-1100 (2013).
8. Terasaki, M. et al. J. Clin. Oncol. 29, 337-344 (2011).
9. Noguchi, M. et al. Prostate 72, 834-845 (2012).
10. Carbone, D. P. et al. J. Clin. Oncol. 23, 5099-5107 (2005).
11. Rahma, O. E. et al. J. Transl. Med. 8, 8 (2010).
12. Lifton, R. P. N. Engl. J. Med. 362, 1235-1236 (2010).
13. Rammensee, H. G. et al. Immunogenetics 41, 178-228 (1995).
14. Weinschenk, T. et al. Cancer Res. 62, 5818-5827 (2002).
15. European Medicines Agency. Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products CHMP/ SWP/28367/07; http://www. ema. europa. eu/docs/en- GB/document-library/Scientific-guideline/2009/09/ WC500002988. pdf (EMA, London, 2007).